Sage Therapeutics, Inc.
SAGE · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | $32 | $14 | $13 | $12 |
| % Growth | 125.1% | 9.7% | 8% | – |
| Cost of Goods Sold | -$0 | $1 | $1 | $5 |
| Gross Profit | $32 | $13 | $11 | $7 |
| % Margin | 100.2% | 95.3% | 88.4% | 55.5% |
| R&D Expenses | $24 | $23 | $37 | $55 |
| G&A Expenses | $62 | $0 | $55 | $53 |
| SG&A Expenses | $62 | $58 | $55 | $53 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $1 | $22 | $0 |
| Operating Expenses | $86 | $81 | $114 | $108 |
| Operating Income | -$54 | -$67 | -$102 | -$101 |
| % Margin | -170.5% | -479.7% | -797.4% | -852.5% |
| Other Income/Exp. Net | $4 | $5 | $6 | $8 |
| Pre-Tax Income | -$50 | -$62 | -$96 | -$94 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$50 | -$62 | -$96 | -$94 |
| % Margin | -156.8% | -442.4% | -747.3% | -788.1% |
| EPS | -0.79 | -1.01 | -1.57 | -1.53 |
| % Growth | 21.8% | 35.7% | -2.6% | – |
| EPS Diluted | -0.79 | -1.01 | -1.57 | -1.53 |
| Weighted Avg Shares Out | 63 | 62 | 61 | 61 |
| Weighted Avg Shares Out Dil | 63 | 62 | 61 | 61 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4 | $5 | $6 | $8 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$54 | -$67 | -$80 | -$101 |
| % Margin | -170.9% | -479.7% | -625.9% | -850.4% |